The casual answer to this question seems obvious, we would say “Yes”. Markets in these countries offer very favourable growth, usually double-digit, and their populations are several times larger than that of countries within the EU. Consider, for example, a…
I had an interesting discussion with one of the biotech entrepreneurs last week. He was curious to see that when he discusses the value of his product with the VCs, he gets a very different value. On the other hand…
La respuesta ”a bote pronto” a esta pregunta parece evidente, diríamos que Sí. Los mercados en estos paises ofrecen crecimientos muy importantes, normalmente de doble digito, siendo sus poblaciones varias veces superiores a la de paises de la EU, por…
These were the exact words from the management of a biotech company based in an emerging market when we were negotiating a deal with them. The company was supposed to in license the product, develop it and launch in its…
La respuesta ”a bote pronto” a esta pregunta parece evidente, dir?amos que S?. Los mercados en estos pa?ses ofrecen crecimientos muy importantes, normalmente de doble d?gito, siendo sus poblaciones varias veces superiores a la de pa?ses de la EU, por…
Risk is an integral part of valuation. When we try to value a company or equity, we use the cost of capital or the cost of equity as the discount rate. For equity investors, the cost of equity is the…
Following the Wold Health Organisation?s approval of India?s vaccine regulatory system two weeks ago there has been much speculation over what the future holds for India?s Vaccine Industry. By achieving WHO approval the Industry has reached an important milestone that projects a bright…
The company ABC borrowed 50 M USD at 2% interest rate 3 years ago. What should be the cost of debt in calculating the cost of capital of the company? Should you use 2% as the cost of debt as…
In my last VIEW post, I discussed the difference between Cost of Capital of a project versus Cost of Capital of a company. In this post we understand whose discount rate we should use when valuing cash flows from out licensing. A…
The subject may sound strange but it is true that one encounters such instances in day to day business deals. I was part of one of the out licensing deals of my Client A, a biotech company that was interested…